Back to Journals » Patient Preference and Adherence » Volume 19

Preferences and Attitudes Towards Digital Communication and Symptom Reporting Methods in Clinical Trials [Response to Letter]

Authors McDowell B, Dumais KM, Gary ST, de Gooijer I, Ward T

Received 15 February 2025

Accepted for publication 4 March 2025

Published 19 March 2025 Volume 2025:19 Pages 659—660

DOI https://doi.org/10.2147/PPA.S522982



Bryan McDowell,1 Kelly M Dumais,2 Sarah Tressel Gary,2 Ingeborg de Gooijer,2 Tomás Ward3

1eCOA Science, Clario, Geneva, Switzerland; 2eCOA Science, Clario, Philadelphia, PA, USA; 3Insight Science Foundation Ireland Research Centre for Data Analytics, Dublin City University, Dublin, Ireland

Correspondence: Bryan McDowell, eCOA Science, Clario, Chemin Louis-Hubert 2, Petit-Lancy, Geneva, 1213, Switzerland, Tel +41 22 879 91 00, Fax +41 22 879 91 01, Email [email protected]


View the original paper by Mr McDowell and colleagues

This is in response to the Letter to the Editor


Dear editor

We thank Luthfiyah S, Triwiyanto T, Ismath M for their interest in our study and their letter recommending areas of further exploration to strengthen the study’s implications.

We acknowledge their suggestions of further research to build upon our findings, which we genuinely believe could add additional value and are worth exploring.

Disclosure

Sarah Gary reports being an employee of Clario. The authors report no other conflicts of interest in this communication.

Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.